Patent Issued for Multi-component injection (USPTO 11986553).

Tianjin Chase Sun Pharmaceutical Co. Ltd. has been granted a patent for a multi-component injection based on traditional Chinese medicine principles. The injection is designed to treat sepsis, a life-threatening infection. It contains active ingredients that have been shown to have pharmacological effects such as fighting bacterial endotoxins, reducing inflammation, and improving immune dysfunction. Clinical studies have demonstrated that the injection can lower mortality rates, shorten hospital stays, and improve outcomes for sepsis patients. The patent provides details on the specific ingredients and the method of preparation, which involves extracting and filtering natural compounds and plant extracts. The resulting injection has a pH value of 5.5-7.0 and can be administered through various injection methods. The patent is owned by Tianjin Chase Sun Pharmaceutical Co. Ltd. and was filed in April 2021. [Extracted from the article]